OKX is set to start spot trading for two tokenized stocks, xIREN and xASML, paired with USD Coin (USDC) on November 4. Trading for xIREN/USDC will begin at 12:30 p.m. ET, followed by xASML/USDC at 1 p.m. ET. This move follows a similar launch for xWDC/USDC trading on October 22, which included a one-hour order placement window before trading started. The addition of these tokenized stock markets expands OKX's offerings for digital asset investors.
The news about OKX launching xIREN and xASML USDC trading pairs provides context for digital asset markets. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 05, 2026 01:32 WIB: out of 50 priced major cryptocurrencies, 44 rose and 5 fell today. Notable movers include EOS at Rp12.649 with an 8.13% increase and a typical hold time of 87 days, ALGO at Rp1.809 with a 6.29% rise and 94% buy order activity, and CRV at Rp5.038 with a 6.13% gain and 69% buy order activity.
Goldman Sachs Group, Inc. disclosed that it briefly held a combined stake exceeding 3% in Ontex Group NV shares as of October 27, 2026, with 566,115 voting rights and 1,965,157 financial instruments. However, by October 28, 2026, their combined posit...
BNP Paribas announced its monthly declaration of voting rights and shares as of October 31, 2026. The bank reported a total of 1,101,600,607 shares and an equal number of voting rights. This update is part of regulatory compliance under French commer...
Ontex disclosed that Goldman Sachs Group, Inc. crossed the 3% ownership threshold in Ontex shares on October 27, 2026, holding a combined total of 3.07% including voting rights and financial instruments. However, the next day, October 28, 2026, Goldm...
Neion Bio has appointed John A. Maga, Ph.D., as Head of Biologics and CMC to lead the development of biologic medicines using its Raptor platform, which produces proteins in transgenic chicken eggs. Maga brings over 25 years of biopharmaceutical expe...
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
